SCHEMBL370283

SCHEMBL370283

Clc1[nH]ncc1-c1csc(Nc2ccccn2)n1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 4/20 0.76
MECP2 P51608 1/20 0.61
KCNN1 Q92952 1/20 0.61
KCNN2 Q9H2S1 1/20 0.61
MBD2 Q9UBB5 1/20 0.61
KCNN3 Q9UGI6 1/20 0.61
KCNH2 Q12809 3/20 0.61
NPC1 O15118 13/20 0.60
RAB9A P51151 12/20 0.60
MEN1 O00255 10/20 0.60
KMT2A Q03164 10/20 0.60
SMN1; SMN2 Q16637 5/20 0.59
MAPT P10636 4/20 0.59
TP53 P04637 3/20 0.59
NFKB1 P19838 3/20 0.59
NFKB2 Q00653 3/20 0.59
RELA Q04206 3/20 0.59
LMNA P02545 2/20 0.59
MAPK1 P28482 2/20 0.59
TDP1 Q9NUW8 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370418 0.83 GRM4 (0.70) GRM4MECP2KCNN1KCNN2MBD2
SCHEMBL370126 0.83 GRM4 (0.73) GRM4MECP2KCNN1KCNN2MBD2
SCHEMBL18029516 0.79 MECP2 (0.63) GRM4MECP2KCNN1KCNN2MBD2
SCHEMBL27800934 0.77 MECP2 (0.77) GRM4MECP2KCNN1KCNN2MBD2
SCHEMBL30745771 0.77 KCNN1 (1.00) MECP2KCNN1KCNN2MBD2KCNN3
SCHEMBL7552748 0.77 NPC1 (0.91) GRM4MECP2KCNN1KCNN2MBD2
SCHEMBL5155715 0.77 KCNN1 (1.00) MECP2KCNN1KCNN2MBD2KCNN3
SCHEMBL18029570 0.76 NPC1 (0.79) GRM4MECP2KCNN1KCNN2MBD2
SCHEMBL31060271 0.76 GRM4 (1.00) GRM4MECP2KCNN1KCNN2MBD2
SCHEMBL366994 0.76 GRM4 (1.00) GRM4MECP2KCNN1KCNN2MBD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073907-B2 Thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA S.A. (CH) 2015-07-07 US claimed
EP-2376486-B1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2013-11-06 EP claimed
US-9073907-B2 Thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA S.A. (CH) 2015-07-07 US disclosed
EP-2376486-B1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2013-11-06 EP disclosed
US-20110257179-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257179-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM2, GRM1 GRM4 1/4885MECP2 204/4885KCNN1 732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.